| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.EJCA.2011.04.006 |
| P698 | PubMed publication ID | 21561763 |
| P50 | author | Tanja Trarbach | Q62761580 |
| P2093 | author name string | M Weihrauch | |
| P R Galle | |||
| J T Hartmann | |||
| A Mueller | |||
| D Wachtlin | |||
| M Moehler | |||
| S E Al-Batran | |||
| P Reimer | |||
| F Lordick | |||
| M P Ebert | |||
| S Biesterfeld | |||
| German Arbeitsgemeinschaft Internistische Onkologie (AIO) | |||
| M Kabisch | |||
| P433 | issue | 10 | |
| P921 | main subject | biomarker | Q864574 |
| multicenter clinical trial | Q6934595 | ||
| phase II clinical trial | Q42824440 | ||
| P304 | page(s) | 1511-1520 | |
| P577 | publication date | 2011-05-09 | |
| P1433 | published in | European Journal of Cancer | Q332260 |
| P1476 | title | An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer | |
| P478 | volume | 47 |
| Q58547850 | A systematic review and meta-analysis on the effect of angiogenesis blockade for the treatment of gastric cancer |
| Q38578404 | Angiogenesis inhibitors in gastric and gastroesophageal junction cancer |
| Q39067386 | Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review |
| Q35005019 | Benchmarking of gastric cancer sensitivity to anti-cancer drugs ex vivo as a basis for drug selection in systemic and intraperitoneal therapy |
| Q38627885 | Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib |
| Q28066550 | Beyond HER2: recent advances and future directions in targeted therapies in esophagogastric cancers |
| Q38263841 | Clinical management of advanced gastric cancer: the role of new molecular drugs. |
| Q36770478 | Clinicopathological features and outcomes of patients with gastric cancer: A single-center experience |
| Q26801289 | Critical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancers |
| Q96132801 | Current Molecular Targeted Agents for Advanced Gastric Cancer |
| Q28079362 | Efficacy and safety of angiogenesis inhibitors in advanced gastric cancer: a systematic review and meta-analysis |
| Q52682256 | Efficacy and safety of targeting VEGFR drugs in treatment for advanced or metastatic gastric cancer: a systemic review and meta-analysis |
| Q38110962 | Emerging tyrosine kinase inhibitors for esophageal cancer |
| Q50878183 | Evidence for angiogenesis-independent contribution of VEGFR1 (FLT1) in gastric cancer recurrence. |
| Q27028079 | Gastric Cancer: New Drugs - New Strategies |
| Q38041643 | Helicobacter pylori: Gastric Cancer and Extragastric Intestinal Malignancies |
| Q41907024 | Metastatic gastric cancer - focus on targeted therapies |
| Q38161727 | Molecular targeted agents for gastric cancer: a step forward towards personalized therapy. |
| Q36705689 | Molecular targeted therapy for advanced gastric cancer |
| Q34326593 | Molecular targeting to treat gastric cancer |
| Q59136693 | New drug developments in metastatic gastric cancer |
| Q38019657 | Novel targeted agents for gastric cancer |
| Q33633424 | Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients |
| Q33420495 | Phase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer |
| Q37958152 | Phase I and II Clinical Trials for Gastric Cancer |
| Q46203603 | RNAi-mediated gene silencing of vascular endothelial growth factor-C inhibits tumor lymphangiogenesis and growth of gastric cancer in vivo in mice |
| Q94602735 | Ramucirumab plus paclitaxel or FOLFIRI in platinum-refractory advanced or metastatic gastric or gastroesophageal junction adenocarcinoma-experience at two centres |
| Q35927364 | Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. |
| Q38921009 | Sorafenib reverses resistance of gastric cancer to treatment by cisplatin through down-regulating MDR1 expression |
| Q30313895 | Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program |
| Q38041732 | Targeted Therapy for Gastric Adenocarcinoma |
| Q38939088 | Targeted therapies for advanced and metastatic adenocarcinoma of the gastroesophageal junction: is there something new? |
| Q38731943 | Targeted therapies in gastric cancer treatment: where we are and where we are going. |
| Q38007119 | Targeted therapy for gastric cancer. |
| Q37341824 | Targeted therapy in gastric cancer. |
| Q36294579 | Targeted therapy in gastroesophageal cancers: past, present and future |
| Q38268000 | Targeting platelet-derived growth factor (PDGF) signaling in gastrointestinal cancers: preclinical and clinical considerations |
| Q33889468 | VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). |
Search more.